EDITORIAL SECTION

In the rapidly evolving world of senior living and longterm care LTC artificial intelligence AI is emerging as a gamechanger From enhancing resident wellness to optimizing operational efficiency AI is transforming how facilities deliver care amid challenges like workforce shortages and the impending

In an era where healthcare costs are skyrocketing and patient outcomes are under scrutiny valuebased care has emerged as a pivotal model for delivering highquality costeffective services Unlike traditional feeforservice systems that reward volume over results valuebased care prioritizes patient outc...

Novartis today announced that the European Commission EC has approved Itvisma onasemnogene abeparvovec for the treatment of children two years and older teens and adults living with q spinal

Imviva Biotech a clinicalstage biotechnology company developing nextgeneration allogeneic CART cell therapies today announced that the US Food and Drug Administration FDA has granted authorization

Abbisko Therapeutics has entered into a strategic collaboration with AstraZeneca to jointly advance the clinical development of a combination therapy for nonsmall cell lung cancer NSCLC

Insilico Medicine has entered into a strategic collaboration with Takeda to use its proprietary PharmaAI platform to support the discovery and development of new drug candidates across Takedas therapeutic areas

Abbisko Therapeutics has entered into a strategic collaboration with AstraZeneca to jointly advance the clinical development of a new immunooncology and targeted therapy combination for the treatment of nonsmall cell lung cancer NSCLC

Monopar Therapeutics has received Rare Pediatric Disease RPD designation from the US Food and Drug Administration FDA for ALXN tiomolibdate choline its latestage investigational treatment for Wilson disease

Roche has launched AXELIOS a nextgeneration sequencing platform based on its proprietary sequencing by expansion SBX technology The platform combines high accuracy speed flexibility scalability and cost efficiency

Innovent Biologics and Eli Lilly and Company have entered into a distribution and promotion agreement for Verzenios abemaciclib in mainland China